English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The efficacy and safety of polaprezinc combined with triple therapy was compared with triple therapy alone in the eradication of  Helicobacter pylori . A randomized, parallel-group, open-label, controlled, prospective multicenter study was conducted in 11 cities in China. Treatment-naive patients with  H .  pylori –associated gastritis were randomly assigned to one of three arms for a 14-day treatment: Arm A triple therapy (omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily) plus polaprezinc 75 mg twice daily; Arm B triple therapy plus polaprezinc 150 mg twice daily, or Arm C triple therapy alone. The rate of  H .  pylori  eradication was the primary endpoint. Secondary endpoints were symptom improvement and lower incidence of adverse events. 303 patients completed the study– 106, 96, and 101 patients in Arms A, B, and C, respectively. Intention-to-treat (ITT) analysis showed that the rate of  H .  pylori  eradication was significantly higher for Arms A (77.0%) and B (75.9%) compared to Arm C (58.6%) ( P  < 0.01), whereas there was no difference between Arms A and B ( P  = 0.90). Per-protocol (PP) analysis showed that the rate of  H .  pylori  eradication was significantly higher for Arms A (81.1%) and B (83.3%) compared to Arm C (61.4%) ( P  < 0.01), whereas there was no significant difference between Arms A and B ( P  = 0.62). All three groups reported significant symptom improvement at 7, 14, and 28 days after treatment, compared to baseline ( P  < 0.0001). The adverse event rate for Arm B (5.1%) was higher than for Arms A (2.8%) ( P  = 0.04) and C (1.9%) ( P  = 0.02). There were no serious adverse events in any group. It appears that standard dose polaprezinc combined with triple therapy can significantly improve the  H .  pylori  eradication rate, without an increase in toxicity.

plos one

Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial